GSK (GSK) Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 4 sell ratings, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings or view top-rated stocks.

10 brokerages have issued twelve-month price objectives for GSK's stock. Their GSK share price forecasts range from $1,400.00 to $1,730.00. On average, they anticipate the company's stock price to reach $1,527.50 in the next twelve months. This suggests a possible upside of 4,223.5% from the stock's current price.
View analysts price targets for GSK or view top-rated stocks among Wall Street analysts.

GSK's stock was trading at $35.14 at the beginning of the year. Since then, GSK shares have increased by 0.5% and is now trading at $35.33.
View the best growth stocks for 2023 here.

GSK saw a increase in short interest in June. As of June 30th, there was short interest totaling 4,700,000 shares, an increase of 22.4% from the June 15th total of 3,840,000 shares. Based on an average trading volume of 3,100,000 shares, the short-interest ratio is presently 1.5 days. Currently, 0.2% of the company's stock are short sold.
View GSK's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our GSK earnings forecast.

GSK plc (NYSE:GSK) posted its earnings results on Tuesday, February, 2nd. The pharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.64 by $0.02. The pharmaceutical company earned $8.74 billion during the quarter, compared to the consensus estimate of $8.71 billion. GSK had a net margin of 50.26% and a trailing twelve-month return on equity of 55.93%. GSK's quarterly revenue was down 1.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.39 earnings per share.
Read the conference call transcript.

GSK announced a quarterly dividend on Wednesday, July 26th. Stockholders of record on Friday, August 18th will be given a dividend of $0.3613 per share on Thursday, October 12th. This represents a $1.45 annualized dividend and a yield of 4.09%. The ex-dividend date is Thursday, August 17th.
Read our dividend analysis for GSK.

ETFs with the largest weight of GSK (NYSE:GSK) stock in their portfolio include VanEck Pharmaceutical ETF (PPH), Subversive Mental Health ETF (SANE), Sound Equity Dividend Income ETF (DIVY), Sound Equity Income ETF (SDEI), Pacer BioThreat Strategy ETF (VIRS), Horizon Kinetics Medical ETF (MEDX), Altrius Global Dividend ETF (DIVD) and B.A.D. Etf (BAD).

GSK (NYSE:GSK) pays an annual dividend of $1.41 per share and currently has a dividend yield of 4.00%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 16.10%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GSK will have a dividend payout ratio of 36.15% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GSK.

GSK updated its FY 2023 earnings guidance on Wednesday, July, 26th. The company provided earnings per share guidance of $1.99-$2.05 for the period, compared to the consensus EPS estimate of $3.80. The company issued revenue guidance of $39.63 billion-$40.37 billion, compared to the consensus revenue estimate of $37.43 billion.

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).

GSK trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

GSK's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.68%), JTC Employer Solutions Trustee Ltd (0.67%), Acadian Asset Management LLC (0.21%), Equity Investment Corp (0.16%), Renaissance Technologies LLC (0.15%) and Hotchkis & Wiley Capital Management LLC (0.14%).
View institutional ownership trends.

Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GSK stock can currently be purchased for approximately $35.33.

GSK (NYSE:GSK) has a market capitalization of $72.34 billion and generates $36.28 billion in revenue each year. The pharmaceutical company earns $18.50 billion in net income (profit) each year or $8.76 on an earnings per share basis.

The company employs 69,400 workers across the globe.

GSK's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The official website for the company is www.gsk.com. The pharmaceutical company can be reached via phone at 442080475000, via email at gsk.investor-relations@gsk.com, or via fax at 44-20-8047-7807.